Evidence map›Paper›PMID 41699199›Full record

Observational studySpinal cord2026

Adverse in-hospital outcomes after major cancer surgery in paraplegic patients.

Andrea Marmiroli, Natali Rodriguez Peñaranda, Mattia Longoni, Quynh Chi Le, Fabian Falkenbach, Michele Nicolazzini, Calogero Catanzaro, Jordan A Goyal, Stefano Luzzago, Francesco Alessandro Mistretta and 11 more

Abstract readObservational Study
In one paragraph

Observational study in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Andrea MarmiroliCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada. andrea.marmiroli@unimi.it.ORCID 0009-0005-7241-8793
Natali Rodriguez PeñarandaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Mattia LongoniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Quynh Chi LeCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Fabian FalkenbachCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.ORCID 0000-0003-1907-3982
Michele NicolazziniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Calogero CatanzaroCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Jordan A GoyalCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Stefano LuzzagoDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti, 435, Milan, Italy.
Francesco Alessandro MistrettaDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti, 435, Milan, Italy.
Mattia PiccinelliDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti, 435, Milan, Italy.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Alberto BrigantiVita-Salute San Raffaele University, Milan, Italy.
Felix K H ChunGoethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.
Salvatore MicaliDepartment of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy.
Markus GraefenMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Carlotta PalumboPiedmont, Maggiore della Carità Hospital, Novara, Italy.
Riccardo SchiavinaDivision of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy.
Gennaro MusiDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti, 435, Milan, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

designObservational cohort study.

objectiveTo test for the association between paraplegia and adverse in-hospital outcomes after major cancer surgery.

methodsWithin National Inpatient Sample (2000-2019), we identified adult patients who underwent colectomy, radical hysterectomy, lung resection, gastrectomy and pancreatectomy for a primary cancer diagnosis. Descriptive analyses, propensity score matching (PSM, ratio 1:10) and multivariable logistic regression models (LRMs) were fitted.

settingUS.

resultsWe identified 957 (0.3%) paraplegics at colectomy, 250 (0.2%) at radical hysterectomy, 138 (0.3%) at lung resection, 94 (0.3%) at gastrectomy and 75 (0.2%) at pancreatectomy. After PSM and additional multivariable adjustment for patients, surgical and hospital characteristics, paraplegia independently predicted 12 of 12 examined endpoints after colectomy and radical hysterectomy, 11 of 12 after lung resection, 9 of 12 after pancreatectomy and 4 of 12 after gastrectomy. Across the examined surgeries, the magnitude of the increase in adverse in-hospital outcomes ranged from 2.4-3.7-fold for overall complications, 2.4-2.9-fold for intraoperative complications, 2.7-4.8-fold for vascular complications and 1.5-2.3-fold for length of stay ≥75

conclusionAcross the five major oncologic procedures, paraplegic patients consistently exhibited higher rates of adverse in-hospital outcomes. The excess risk was most pronounced after colectomy, radical hysterectomy, and lung resection, moderate after pancreatectomy, and least evident after gastrectomy. Similarly, the magnitude of the disadvantage also varied depending on the definition of adverse in-hospital outcome and major cancer surgery type.

Indexed as

NeoplasmsParaplegiaPostoperative ComplicationsAdultAgedCohort StudiesColectomyFemaleGastrectomyHumansHysterectomyMaleMiddle AgedPancreatectomyPneumonectomy

Identifiers

PMID41699199
PMCPMC13065474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.